Peripheral neuropathies (PN) ultimately affect almost 10 percent of the population. New diagnostic and management options make rational therapies for PN increasingly possible. However, the high cost of certain diagnostic tests and therapies, along with the complexities involved in choosing which tests and treatments to initiate, complicate the management of patients with PN. The Peripheral Nerve Society (PNS) and AAN Neuromuscular Section will present three two-hour courses devoted to the diagnosis and management of these disorders. Faculty will provide an overview of the peripheral nervous system, including a pathological overview of PN, and review the diagnosis and management of acquired immune-based ceuropathies, including Guillain Barre syndrome and CIDP.
This program complements C204: Peripheral Neuropathy II: Diabetic and Inherited Neuropathies and C217: Peripheral Neuropathy III: Genetic Testing and Next Generation Sequencing, but covers independent topics.
Participants should be able to understand the anatomical basis and pathological consequences of peripheral neuropathies, distinguish between acquired and inherited peripheral neuropathies, and use a rational, evidence-based approach to treat acquired immunologically based peripheral neuropathies.
Medical Knowledge, Patient Care
Program Speakers - Tentative
7:00 AM - 7:45 AM
Peripheral Neuropathy—Overview of Anatomy and Pathology
Steven Scherer MD
7:45 AM - 8:30 AM
Diagnosis and Treatment of Acquired Demyelinating Neuropathies
Richard A. Lewis MD, FAAN
8:30 AM - 9:00 AM
Questions and Answers/Case Presentations
Richard A. Lewis MD, FAAN, Steven Scherer MD
Richard A. Lewis, MD, FAAN
Dr. Lewis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with CSL Behring; Axelacare; Pharnext; Biotest; Kedrion; Nufactor; Optioncare; Grifols. Dr. Lewis has received research support from Neutralis; Cytokinetics.
Steven Scherer, MD
Dr. Scherer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Disarm Pharmaceutical.